BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 20332316)

  • 1. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
    Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
    Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
    Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
    J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors.
    Schaub R; Burger A; Bausch D; Niggli FK; Schäfer BW; Betts DR
    Cancer Genet Cytogenet; 2007 Jan; 172(1):61-5. PubMed ID: 17175381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
    Williams RD; Al-Saadi R; Natrajan R; Mackay A; Chagtai T; Little S; Hing SN; Fenwick K; Ashworth A; Grundy P; Anderson JR; Dome JS; Perlman EJ; Jones C; Pritchard-Jones K
    Genes Chromosomes Cancer; 2011 Dec; 50(12):982-95. PubMed ID: 21882282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain of MYCN region in a Wilms tumor-derived xenotransplanted cell line.
    Noguera R; Villamón E; Berbegall A; Machado I; Giner F; Tadeo I; Navarro S; Llombart-Bosch A
    Diagn Mol Pathol; 2010 Mar; 19(1):33-9. PubMed ID: 20186010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
    Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
    Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer.
    Calcagno DQ; Freitas VM; Leal MF; de Souza CR; Demachki S; Montenegro R; Assumpção PP; Khayat AS; Smith Mde A; dos Santos AK; Burbano RR
    BMC Gastroenterol; 2013 Sep; 13():141. PubMed ID: 24053468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
    Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
    World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple mechanisms of MYCN dysregulation in Wilms tumour.
    Williams RD; Chagtai T; Alcaide-German M; Apps J; Wegert J; Popov S; Vujanic G; van Tinteren H; van den Heuvel-Eibrink MM; Kool M; de Kraker J; Gisselsson D; Graf N; Gessler M; Pritchard-Jones K
    Oncotarget; 2015 Mar; 6(9):7232-43. PubMed ID: 25749049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
    Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
    Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratification of Wilms tumor by genetic and epigenetic analysis.
    Scott RH; Murray A; Baskcomb L; Turnbull C; Loveday C; Al-Saadi R; Williams R; Breatnach F; Gerrard M; Hale J; Kohler J; Lapunzina P; Levitt GA; Picton S; Pizer B; Ronghe MD; Traunecker H; Williams D; Kelsey A; Vujanic GM; Sebire NJ; Grundy P; Stiller CA; Pritchard-Jones K; Douglas J; Rahman N
    Oncotarget; 2012 Mar; 3(3):327-35. PubMed ID: 22470196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responsiveness of chemotherapy based on the histological type and Wilms' tumor suppressor gene mutation in bilateral Wilms' tumor.
    Shibata R; Takata A; Hashiguchi A; Umezawa A; Yamada T; Hata J
    Pathol Int; 2003 Apr; 53(4):214-20. PubMed ID: 12675764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
    Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
    J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
    Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
    BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutional 560.49 kb chromosome 2p24.3 duplication including the MYCN gene identified by SNP chromosome microarray analysis in a child with multiple congenital anomalies and bilateral Wilms tumor.
    Micale MA; Embrey B; Macknis JK; Harper CE; Aughton DJ
    Eur J Med Genet; 2016 Dec; 59(12):618-623. PubMed ID: 27794475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identical genetic changes in different histologic components of Wilms' tumors.
    Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
    J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The epithelial mesenchymal transition process in wilms tumor: a study based on a xenograft model.
    Giner F; Machado I; Noguera R; Villamon E; Pellin A; Calabuig-Fariñas S; Peydro-Olaya A; Navarro S; Llombart-Bosch A
    Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):369-75. PubMed ID: 21285869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
    Ruteshouser EC; Robinson SM; Huff V
    Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.